2003
DOI: 10.1016/s0006-291x(03)00828-3
|View full text |Cite
|
Sign up to set email alerts
|

Peptide-based, irreversible inhibitors of γ-secretase activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2006
2006
2010
2010

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 47 publications
0
3
0
Order By: Relevance
“…Examples include EPNP (1,2-epoxy-3-(p-nitrophenoxy)propane), which is a well known unspecific irreversible inhibitor of aspartic proteases, [14][15][16] and cis-configured epoxides known to inhibit HIV-1 protease (Figure 2), [17][18][19][20][21][22] SIV protease, [23] and g-secretase known to be involved in Alzheimer's disease. [24] The cis-configuration is considered necessary for steric reasons ( Figure 3). …”
Section: Introductionmentioning
confidence: 99%
“…Examples include EPNP (1,2-epoxy-3-(p-nitrophenoxy)propane), which is a well known unspecific irreversible inhibitor of aspartic proteases, [14][15][16] and cis-configured epoxides known to inhibit HIV-1 protease (Figure 2), [17][18][19][20][21][22] SIV protease, [23] and g-secretase known to be involved in Alzheimer's disease. [24] The cis-configuration is considered necessary for steric reasons ( Figure 3). …”
Section: Introductionmentioning
confidence: 99%
“…However, one pharmacologically interesting feature resides in the fact that Aβ production from cells treated with peptide aldehydes recovers within the first 2 hours of washout as assayed by ELISA, indicating that this type of inhibitors are reversible. In contrast, use of their corresponding epoxides under the same conditions show an Aβ-recovering activity after 8 hours only, indicating that these epoxides constitute some irreversible γ-secretase inhibitors [142]. Based on these studies, compounds 24 and 25 (Fig.…”
Section: Collaboration Between Elan Pharmaceuticals and Elimentioning
confidence: 87%
“…All of these compounds also tested positive for Notch inhibition, either in vivo (Taniguchi et al 2002) or in vitro (Beck & Slack 2002). More recent inhibitors that are also known to modulate Notch include a hydroxyethylene peptidomimetic named L-685,458 (Shearman et al 2000, Sernee et al 2003 together with its homologous counterpart III-31-C (Li et al 2000, Esler et al 2002, the structurally related compounds D and E (Seiffert et al 2000, Beher et al 2001, CBAP (Beher et al 2001), LY411575 (Dovey et al 2001, Wong et al 2004), a dibenzazepine and benzodiazepine (Milano et al 2004), and a group of epoxides consisting of compounds IL, ILX, and KILX (Piper et al 2003). The abundance of pharmacological inhibitors of Notch signaling makes this another attractive target for inclusion in future in vitro differentiation protocols, as shown in Fig.…”
Section: The Notch Signaling Pathwaymentioning
confidence: 99%